Sign In
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- US Share Prices
- Stock Tips
- Share Chat
- FX
- News & RNS
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Oxford Biomedica Share News (OXB)
OXB Share
Price
OXB Share
News
OXB Share
Chat
OXB Share
Trades518
OXB
Live RNS
OXB Share
Charts
OXB Level 2
Console
OXB Live
Share Price
OXB Broker
Ratings
OXB Directors
Deals
OXB Financial
Diary
OXB
Fundamentals
OXB Short
Positions1
OXB
Media
OXB Company
Research
OXB Company
Timeline1
Oxford Biomedica Information
Share Price Information for Oxford Biomedica (OXB)
Share Price is delayed by 15 minutes
Get Live Data
601.00
-3.00 (-0.50%)
Bid:
600.00
Ask:
601.00
Spread:
1.00 (0.167%)
Market Cap:
£727.26m
Last checked at -
Last checked at 
Intraday Oxford Biomedica Share Chart
Oxford Biomedica News
28 Jan 2022
UPDATE: Oxford BioMedica raises GBP80 million via placing
UPDATE: Oxford BioMedica raises GBP80 million via placing
28 Jan 2022
LONDON MARKET CLOSE: Stocks close out rollercoaster week with losses
LONDON MARKET CLOSE: Stocks close out rollercoaster week with losses
28 Jan 2022
CORRECT: Oxford BioMedica to acquire 80% ownership of new US business
CORRECT: Oxford BioMedica to acquire 80% ownership of new US business
28 Jan 2022
LONDON MARKET MIDDAY: Stocks sink on Ukraine tensions and hawkish Fed
LONDON MARKET MIDDAY: Stocks sink on Ukraine tensions and hawkish Fed
28 Jan 2022
Oxford BioMedica to acquire 80% ownership of new US virus business
Oxford BioMedica to acquire 80% ownership of new US virus business
28 Jan 2022
Oxford Biomedica creates venture with Homology, launches £80m fundraise
(Sharecast News) - Cell and gene therapy specialist Oxford Biomedica announced an agreement with Homology Medicines on Friday, as well as a placing to...
17 Jan 2022
Oxford Biomedica starts search for new CEO as Dawson steps down
Oxford Biomedica starts search for new CEO as Dawson steps down
17 Jan 2022
Oxford Biomedica CEO John Dawson to step down
(Sharecast News) - Oxford Biomedica chief executive John Dawson said he was stepping down after 13 years at the helm of the Gene and cell therapy firm...
Follow the stocks
